Pharma: Other News To Note
Wednesday, December 12, 2012
Eisai Inc., of Woodcliff Lake, N.J., said the FDA determined that the company has met the agency's written request requirements for pediatric exclusivity for Aciphex (rabreprazole sodium). As a result, Eisai now has gained an additional six months of U.S. market exclusivity for Aciphex, which will expire on Nov. 8, 2013.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.